Company identity
Company Name: Abbot Laboratories (Pakistan) Ltd
Ticker: ABOT
Official issuer name: Abbott Laboratories (Pakistan) Limited. The company is a Pakistan-incorporated, Pakistan Stock Exchange-listed healthcare business. It was incorporated on July 2, 1948, and its registered office is in Landhi, Karachi. Abbott Asia Investments Limited of the United Kingdom owns 77.90% of the shares, while Abbott Laboratories in the United States is the ultimate holding company. That ownership gives the local company access to a global healthcare platform, but ABOT’s reported earnings remain shaped by Pakistani demand, regulation, currency and operating costs. Official company profile
The company in one view
Abbott Pakistan is not a single-product drug manufacturer. It is a diversified healthcare operating company with four reporting segments: pharmaceuticals, nutrition, diagnostics and “others,” which includes diabetes care and general healthcare. It manufactures some products locally, imports others, markets them through a nationwide commercial network and supports diagnostic equipment placed with healthcare customers. The economic engine is therefore a blend of factory output, imported finished goods and inputs, regulated or market-linked pricing, brand demand, distribution reach and technical support. 2025 Annual Report
Pharmaceuticals are the largest segment and the main earnings driver. Nutrition adds a consumer-health dimension, while diagnostics is more equipment-, reagent- and tender-oriented. Diabetes care and general healthcare broaden the portfolio further. This mix reduces dependence on a single market, yet each segment behaves differently: prescription demand can be seasonal, nutrition is sensitive to household affordability, diagnostics can move with institutional budgets and tenders, and imported products expose the company to foreign-exchange and freight conditions. Understanding ABOT means separating these engines instead of treating every rupee of sales as economically identical. Q1 2026 Interim Report
How the business developed
Abbott has operated in Pakistan since 1948. The local company evolved from a marketing presence into a substantial manufacturing and distribution platform. Its official materials describe two manufacturing facilities in Karachi, commercial offices in major cities and distribution depots serving the national market. The 2025 annual report lists more than 1,300 employees, while Abbott’s current Pakistan website says more than 1,400 employees across its home office, plants, sales offices and depots. The difference is best read as a timing or reporting-scope difference, not combined into a new estimate. Abbott in Pakistan
What Abbott Pakistan sells
Pharmaceuticals
The pharmaceutical segment manufactures, imports and markets branded generic medicines registered with the Drug Regulatory Authority of Pakistan. The portfolio covers digestive health, women’s health, respiratory conditions, central nervous system and pain management, and influenza vaccines. Demand is created through medical need, physician familiarity, product availability and commercial execution. The annual report described a portfolio of more than 150 stock-keeping units in 2025, so the segment’s result is the combined outcome of many brands, presentations and therapeutic categories rather than one blockbuster. 2025 Annual Report
Its revenue model is straightforward but economically layered: sell packs through distributors and institutional channels, deduct returns, trade discounts, sales tax and excise duty, and then absorb manufacturing or imported-product cost plus selling expenditure. Price adjustments can lift revenue faster than volume, while volume growth can improve plant utilization and spread fixed manufacturing costs. The reverse is also true: weak seasonal illness, lower patient footfall or affordability pressure can reduce volume even when list prices are higher. Q1 2026 Interim Report
Nutrition
The nutrition segment imports and markets science-based nutritional products. It has a different customer journey from prescription medicines: consumers, caregivers, doctors, pharmacies and retail availability can all influence demand. Because finished goods are imported, landed cost can move with exchange rates, freight, duties and supplier pricing. In 2025, management said nutrition sales rose 8.95% mainly because of price adjustments, partly offset by lower volume. That distinction matters: nominal sales growth is less powerful when it comes from price alone and the number of units sold is falling. 2025 Annual Report
Diagnostics, diabetes care and general healthcare
Diagnostics imports and markets diagnostic equipment, molecular devices and testing kits. Its economics can include an installed base of instruments followed by recurring reagent and consumable demand, but the precise commercial terms vary by product and customer and should not be assumed. Hospitals, laboratories, government institutions and other healthcare providers are important end-markets. Tender timing can make results uneven: management attributed the 18.24% decline in 2025 diagnostics sales mainly to lost tenders in one division after a shift in government spending, partly offset by price increases. 2025 Annual Report
Assets, production and operating footprint
Abbott Pakistan’s manufacturing base consists of two Karachi facilities, with the registered Landhi site and another facility in Korangi Industrial Area identified in the financial statements. Sales offices and warehouses extend the physical network into other cities. The plants are multiproduct operations: tablets or other solids, liquids, injectables, creams and general-healthcare products do not share one simple unit of capacity. The company therefore says installed capacity is indeterminable and production is scheduled according to market demand. 2025 Annual Report
Actual 2025 output was 232.11 million units, up from 219.28 million in 2024. Liquids increased to 158.61 million packs from 145.86 million, creams rose to 12.01 million from 11.52 million and general healthcare reached 2.70 million from 1.28 million. Solids declined to 57.81 million from 59.54 million and injectables eased to 0.98 million from 1.08 million. These are physical operating facts, but they should not be converted directly into revenue growth because product mix and selling price per pack differ materially. 2025 Annual Report
Raw materials, imports and critical operating inputs
The core physical inputs include active pharmaceutical ingredients, excipients, packaging materials, imported finished medicines and nutrition products, diagnostic instruments, reagents and testing kits. Production also requires skilled labour, validated machinery, quality-control laboratories, utilities, warehousing and a compliant distribution chain. Abbott disclosed PKR 24.38 billion of raw and packing materials consumed in 2025 and PKR 17.02 billion of finished goods purchased, showing that both local conversion and externally sourced product are economically significant. 2025 Annual Report
Import dependence creates several linked exposures. A weaker rupee raises the local-currency cost of foreign inputs and finished goods; shipping disruption can delay availability; and duties or tax changes alter landed cost. Energy tariffs affect local production and cold-chain or controlled-storage requirements. Management said 2025 product costs benefited from negotiations on major active ingredients and excipients, a lower average exchange rate, duty reductions, lower energy tariffs and conservation initiatives. These are management explanations, not permanent advantages: each can reverse. 2025 Annual Report
Customers, route to market and pricing
The customer chain spans distributors, pharmacies, hospitals, laboratories, government institutions, healthcare professionals and consumers. Abbott reported collaboration with more than 50 distributors nationwide in 2025. Distributors turn factory and imported inventory into countrywide availability, while the company’s sales organization builds professional awareness and supports accounts. A strong brand does not produce revenue if inventory is unavailable at the point of care, so service levels, distributor credit and inventory discipline are central parts of the model. 2025 Annual Report
Pricing is not uniform across the portfolio. Medicines are subject to DRAP’s regulatory framework, with essential medicines receiving particular policy attention; other health products have different competitive and affordability constraints. DRAP maintains the Drug Pricing Policy 2018 as amended and a National Essential Medicines List. Abbott’s management welcomed changes affecting non-essential medicines but said essential medicines still require a robust review and hardship-case process. This is a management position; the policy documents themselves establish the regulatory setting. DRAP Drug Pricing Policy
Revenue, costs, margins and cash conversion
For 2025, net sales rose 10.6% to PKR 75.40 billion from PKR 68.18 billion. Pharmaceuticals grew 15.6%, nutrition 8.95% and diagnostics declined 18.24%. Gross profit increased to PKR 26.45 billion from PKR 19.74 billion, lifting gross margin to 35.1% from 29.0%. Profit after tax rose 52.2% to PKR 7.97 billion and earnings per share reached PKR 81.37, compared with PKR 53.46 in 2024. 2025 Annual Report
The margin expansion was not simply sales growth. Cost of sales increased only 1.0% to PKR 48.95 billion. Management attributed that restraint to procurement negotiations, exchange-rate and duty effects, lower energy costs, conservation and manufacturing efficiencies, offset by higher wages, depreciation and a one-off impairment related to sterile production. Other income also rose, helped by returns on higher cash and a one-off liability write-back. Readers should separate those non-core benefits from recurring product economics. 2025 Annual Report
Cash conversion strengthened materially. Cash generated from operations was about PKR 16.07 billion in 2025, while the company’s free-cash-flow measure rose to PKR 7.44 billion from PKR 1.65 billion. Cash and cash equivalents were PKR 13.34 billion at year-end. Management said favourable working-capital movement in trade payables helped, partly offset by higher inventory and tax payments. That makes working-capital quality important: cash created by stretching payables is not identical to cash created by faster customer collections or structurally lower inventory. 2025 Annual Report
What the latest quarter adds
The March 2026 quarter showed continued profit growth but slower top-line momentum. Net sales were PKR 17.70 billion, 2.1% above PKR 17.35 billion a year earlier. Pharmaceutical net sales were PKR 12.33 billion, nutrition PKR 3.74 billion, diagnostics PKR 1.22 billion and other activities PKR 0.42 billion. Profit after tax increased 21.3% to PKR 1.94 billion and earnings per share rose to PKR 19.82 from PKR 16.34. Q1 2026 Interim Report
Management described reduced patient footfall and a muted respiratory and flu season. Pharmaceutical sales still rose 6%, nutrition fell 5% and diagnostics was broadly flat. Overall gross margin improved to 38% from 34%; pharmaceutical margin reached 38% from 32% and nutrition reached 46% from 42%. The economic reading is mixed but constructive: demand growth was modest, yet cost and mix discipline protected profitability. Whether that margin level persists is more important than one quarter’s percentage alone. Q1 2026 Interim Report
Key facts and figures
- 1948: Incorporated in Pakistan on July 2; shares are quoted on PSX under ABOT. Source
- 77.90%: Shareholding of Abbott Asia Investments Limited, UK, at December 31, 2025. Source
- Two: Manufacturing facilities in Karachi reported for 2025. Source
- More than 1,300: Employees reported in the 2025 annual report. Source
- More than 150: Stock-keeping units in the 2025 portfolio. Source
- 232.11 million: Total units produced in 2025, versus 219.28 million in 2024. Source
- PKR 75.40 billion: Net sales for 2025, up 10.6% year on year. Source
- 35.1%: Gross margin for 2025, compared with 29.0% in 2024. Source
- PKR 7.97 billion: Profit after tax for 2025, up 52.2%. Source
- PKR 3.3 billion: Capital investment during 2025. Source
- PKR 7.44 billion: Company-presented free cash flow for 2025, versus PKR 1.65 billion in 2024. Source
- PKR 17.70 billion: Net sales for the quarter ended March 31, 2026. Source
- PKR 1.94 billion: Profit after tax for the quarter ended March 31, 2026. Source
Competitive position and structural strengths
Abbott Pakistan’s clearest structural strengths are portfolio breadth, established brands, local manufacturing, nationwide distribution and access to a global parent’s systems and products. Diversification can cushion a weak tender cycle or a soft consumer category, while local production reduces—but does not eliminate—dependence on finished imports. Cash resources provide room to fund inventory, capital expenditure and commercial activity. Long operating history and regulatory experience can also be valuable in a market where product quality and continuity matter. 2025 Annual Report
Competition remains intense. Pakistan has large domestic manufacturers, other multinational companies, specialist diagnostic suppliers and consumer-health alternatives. Abbott’s annual report, citing IQVIA, estimated a USD 3.77 billion pharmaceutical market, 678 active companies and a 6.8% Abbott share in 2025. Those are management-reported third-party market estimates, not audited financial-statement measures. They indicate scale, but share can move with pricing, launches, supply, tender outcomes and the measured market definition. 2025 Annual Report
Favourable and adverse operating environments
A favourable environment combines stable exchange rates, predictable regulation, timely price reviews, easing input and energy costs, improving household purchasing power, normal seasonal illness, stronger institutional healthcare budgets and reliable shipping. In that setting, volume and price can work together while fixed factory and commercial costs are spread across a larger revenue base. New registrations, portfolio extensions, capacity improvements and better diagnostic placement can add growth without requiring an entirely new business model. Q1 2026 Interim Report
An adverse environment combines rupee depreciation, oil-led inflation, import disruption, delayed essential-drug price decisions, weak consumer affordability, lower patient visits and restrained government tenders. A poor flu season can soften respiratory demand; weak public spending can reduce diagnostics orders; and higher interest or tax burdens can affect customers and the company. Product-quality failures, recalls or regulatory non-compliance would be especially serious because healthcare trust and licences are foundational assets, even where no such event is presently assumed. DRAP
Growth avenues, risks and what to monitor
Growth can come from deeper penetration of established brands, new products, improved availability, locally manufactured volume, selected exports, diagnostic consumables and operating efficiency. The 2025 production increase and capital programme create potential, but they are not guarantees. Readers should look for evidence that investment produces sustainable gross profit and cash rather than only higher assets. Related-party access may support portfolio breadth, while local capability can lower supply risk when economically and technically feasible. 2025 Annual Report
The central risks are regulatory pricing, foreign exchange, imported input availability, energy and logistics costs, tender volatility, household affordability, competition, product concentration within subcategories, quality compliance and tax or fiscal changes. A diversified portfolio moderates but cannot remove these exposures. Management’s own 2026 outlook also highlighted geopolitical disruption, oil-price inflation and foreign-exchange strain. AlphaGen inference: the most useful early-warning combination is segment volume direction, gross margin and inventory/cash movement—not revenue growth viewed alone. Q1 2026 Interim Report
How to read this company’s results
Start with segment sales, not just consolidated revenue. Separate pharmaceutical, nutrition, diagnostics and other growth, then ask whether change came from price, volume, tender timing or mix. Next compare gross-margin movement with exchange rates, raw-material and finished-goods purchases, energy costs and management’s efficiency claims. A rising margin supported by procurement and manufacturing gains is economically different from one supported mainly by temporary currency movement or price catch-up. 2025 Annual Report
Then bridge operating profit to net profit. Identify other income, write-backs, impairment, finance cost, levies and tax so that recurring product earnings are not confused with one-offs. Finally reconcile profit with operating cash: watch inventory, receivables, distributor credit, payables, capital expenditure and cash balances. For diagnostics, monitor tenders and institutional budgets; for nutrition and diabetes care, watch affordability and volume; for pharmaceuticals, track essential-drug policy, availability and seasonal demand. 2025 Annual Report
Sources
Abbott Laboratories (Pakistan) Limited — 2025 Annual Report Open report
Abbott Laboratories (Pakistan) Limited — First Quarter 2026 Interim Report Open report
Abbott Pakistan — Company Profile Open profile
Pakistan Stock Exchange — ABOT company page Open PSX page
Drug Regulatory Authority of Pakistan — Drug Pricing Policy Open policy page
Drug Regulatory Authority of Pakistan — National Essential Medicines Lists Open NEML page